WeKnowYouKnowThatWeknow 🇦🇺

@AlboMP What’s the point you even finishing up your day. Pack up your desk & get the hell out The confirmation from the President Donald J Trump has been given! #auspol @SkyNewsAust @abcnews @CraigKellyPHON @PaulineHansonOz @TurnbullMalcolm @SenatorWong @SenatorRennick @PeterDutton_MP

BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal 84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION. Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995. The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole. Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability. At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either: No evidence of disease (32.8%) Tumor regression (15.6%) or Cancer stabilization (36.1%) Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months. Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments. This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential. With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required. In the meantime, many cancer patients are exercising their right to try.

One billionaire bankrolls the Senate Republicans blocking Trump — and the Tony Blair operation that tried to drag him into a forever war with Iran. Meet Larry Ellison. @BarbaraMBoyd connects the whole network. 🧵👇

"𝐄𝐯𝐞𝐫𝐲 𝐣𝐨𝐮𝐫𝐧𝐞𝐲 𝐡𝐚𝐬 𝐚𝐧 𝐞𝐧𝐝.”

The LARGEST human ivermectin cancer study EVER conducted found 84% of cancer patients declared COMPLETE REMISSION, TUMOR SHRINKAGE, or HALTED TUMOR GROWTH. Our study is now PEER-REVIEWED and PUBLISHED by the International Institute of Anticancer Research. The tide is turning.

🚨 President Trump just DROPPED this bombshell: FBI whistleblower says thousands of hours of Jan. 6 footage was hidden because federal "human sources" were in the crowd, and Deep State agents were ordered to make up charges against Jan. 6ers Anyone who called it out from inside was "retaliated" against SCANDALOUS COVERUP!

On J6, Twitter erased multiple tweets by Trump urging attendees to go home peacefully. One had a video that Facebook and YouTube also deleted. Regardless of your opinion re: events, there is no valid explanation/reason for taking down posts he made to de-escalate the situation.

Another 764 Network arrest, 33 year prison sentence for a predator who targeted and exploited over 100 children, 150 year sentence for one arrested predator, 91 violent crime arrests out of St. Louis from our national op Operation Viper, $9 million fraud takedown in Baltimore, Operation Setoria saving 80+ kids, and more. Another non-stop week at your @FBI crushing crime all over the country. breitbart.com/politics/2026/…

I hope this goes somewhere!!!

🛡️⚔️⚔️Justice Is Coming🛡️ ⚔️⚔️ NCSWIC

●Catch Up. If you know nothing about the Q Operation, this is a great start.🫡 ●Q is 100% Coming from the Trump Administration.

PRESIDENT TRUMP POST: TIME TO AUDIT FORT KNOX! 💥💥💥💥 😏 GOLD 🙌🏻

Domino's Are Falling The World Is Rising WWG1WGA

BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal 84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION. Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995. The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole. Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability. At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either: No evidence of disease (32.8%) Tumor regression (15.6%) or Cancer stabilization (36.1%) Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months. Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments. This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential. With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required. In the meantime, many cancer patients are exercising their right to try. @twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson

Everything's Connected.

[P]atriots [A]re [N]ow [I]n [C]ontrol DOE-Department Of Energy⚡🔋

Woah I missed this one 2020 Baby 😎 @realDonaldTrump/116428386907912654" target="_blank" rel="nofollow noopener">truthsocial.com/@realDonaldTru…

15 zeros and counting. TradFi numbers, onchain.

@blackjack_god @ecb @Lagarde Did you write your post when you had a stroke and was fully retarded?

There are three conditions for safeguarding central bank independence, says President Christine @Lagarde: 🔹 A clear mandate: price stability 🔹 Direct communication with citizens 🔹 Preserving room for manoeuvre in monetary policy Read the speech ecb.europa.eu/press/key/date…

@ecb @Lagarde This woman is running from this truth 👇

Beware of central bankers who want to preserve “room for maneuver” in monetary policy. This is the mantra of the government-knows-best crowd—not the voice of advocates for free markets and those who demand accountability from the heads of government agencies.